drugset / Trial / NCT03519984
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
Phase 1
Terminated
3 enrolled
University of Southern California
National Cancer Institute (NCI) · collabVasgene Therapeutics, Inc · collabWhittier Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with cytarabine or vincristine liposomal in treating participants with acute leukemia that has come back or has not responded to treatment. Drugs used in chemotherapy, such as recombinant ephb4-HSA fusion protein, cytarabine, and vincristine liposomal, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving the drugs in different combinations may kill more cancer cells.
Timeline
- Start
- 2018-05-09
- Primary completion
- 2020-11-24
- Completion
- 2020-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | — | Intravenous |
| Subject | Vincristine | Small molecule | — | Intravenous |
| Subject | sEphB4-HSA | Protein / enzyme biologic | — | Intravenous |